secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001437749-22-026177
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q3 2022: cash $117.5M, no revenue; FDA authorizes Phase 2 endoxifen study
--------------------------------------------------------------------------------

- Cash, cash equivalents and restricted cash $117.5M as of Sep 30, 2022; no revenue in Q3.
- Operating expenses $8.2M in Q3 2022, up 59% YoY; R&D $5.2M (+134%) on higher trial costs.
- FDA authorized Phase 2 neoadjuvant (Z)-endoxifen for ER+/HER2- breast cancer; enrollment expected Q4 2022.
- Invested in privately-held Dynamic Cell Therapies (CAR-T); paid $300K for exclusive negotiation right.
- Completed dosing in Parts B and C of Phase 1/2a AT-H201 trial for lung injury from cancer treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/0001437749-22-026177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/atos20221103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer